Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

PharmacoEconomics

Volumn 36, Issue 7, 2018, Pages 733-743

  Antoñanzas, Fernando ^a   Rodríguez Ibeas, Roberto ^a   Juárez Castelló, Carmelo A ^a  

^a UNIVERSITY OF LA RIOJA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG TREATMENT FAILURE; FINANCIAL MANAGEMENT; HEALTH AUTHORITY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; LEGAL ASPECT; MATHEMATICAL MODEL; PAY FOR PERFORMANCE; PENALIZATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REIMBURSEMENT; SIMULATION; ECONOMICS; HEALTH CARE DELIVERY; RESEARCH; TREATMENT FAILURE;

DELIVERY OF HEALTH CARE; DRUG INDUSTRY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PRECISION MEDICINE; RESEARCH; TREATMENT FAILURE;

EID: 85042089249     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-018-0619-4     Document Type: Article

References (27)

1. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16:54–9.
2. Antoñanzas F, Juárez-Castelló C, Rodríguez-Ibeas R. Some economics on personalized and predictive medicine. Eur J Health Econ. 2015;16(9):985–94.
3. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(6 Suppl.):S20–6.
4. Sairamesh J, Rossbach M. An economic perspective on personalized medicine. Hugo J. 2013;7(1):1–2.
5. Connor S. Our Drugs Do Not Work On Most Patients. The Independent (London), 13 Dec 2011. http://www.rense.com/general69/glax.htm. Accessed 6 Feb 2018.
6. Culbertson AW, Valentine SJ, Naylor S. Personalized medicine: technological innovation and patient empowerment or exuberant hyperbole? Drug Discov World. 2007;8(3):18–32.
7. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–93.
8. Jain S, Shankaran V. The economics of personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2016;12:123–9.
9. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.
10. Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst. 2012;104(23):1785–95.
11. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.
12. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12(1):20–7.
13. NICE. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. 2015. nice.org.uk/guidance/ta374. Accessed 9 Jan 2018.
14. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J, Personalized Medicine Development and Reimbursement Working Group. Challenges in the development and reimbursement of personalized medicine: payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group. Value Health. 2012;15(8):1162–71.
15. Carlson JJ, Chen S, Garrison LP. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017;35:1063–72.
16. Towse A, Garrison LP. Can’t get no satisfaction? Will pay for performance health? Pharmacoeconomics. 2010;28(2):93–102.
17. de Pouvourville G. Risk-sharing agreements for innovative drugs. Eur J Health Econ. 2006;7:155–7.
18. Pita-Barros P. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ. 2011;20:461–70.
19. Zaric GS, O’Brien BJ. Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econ. 2005;14:793–803.
20. Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion and net health benefits. Value Health. 2009;12(5):838–45.
21. Antoñanzas F, Juaréz-Castelló C, Rodríguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law. 2011;6:391–403.
22. Towse A, Garrison LP. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health. 2013;16(6 Suppl.):S39–43.
23. O’Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health. 2013;16(6 Suppl.):S1–3.
24. Pita-Barros P, Martínez-Giralt X. Health economics: an industrial organization perspective. London, New York: Routledge, Taylor and Francis Group; 2012.
25. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov. 2011;10(11):817–33.
26. Satanove D. The challenging economics of the companion diagnostic industry; a compelling case for patent protection. J Intell Prop Ent Law. 2016;6(1):142–71.
27. Graf von der Schulenburg JM. Frank M. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. Eur J Health Econ. 2015;16(2):113–8.